. Thus, significant immunophenotypic aberrancy in the context of monocytosis appears to be consistent with a monocytic neoplasm, and is a helpful feature in the diagnosis of borderline cases. The findings in the present study further indicate that even when a blast population lacks definitive immunophenotypic evidence of monocytic differentiation, the presence of a large number of aberrant monocytes suggests a monocytic AML.
All seven cases of AML with inv(16)/t(16;16) belonged to group 2 AMML, in that they had distinct populations of blasts and monocytes. Interestingly, the monocytic cells in this subgroup exhibited immunophenotypic abnormalities that distinguished them from other group 2 AMMLs lacking chromosome 16 abnormalities (Table 1) . They more frequently showed two or more monocyte aberrancies (6/7 vs 3/13; P ¼ 0.003). Specifically, CD2 expression in monocytes was identified in 6/6 cases with inv(16)(p13;q22), and was significantly correlated with chromosome 16 abnormalities among AMMLs (6/6 vs 1/11; P ¼ 0.001). The single case of AMML with t(16;16) that exhibited one monocyte aberrancy was not assessed for CD2 expression due to the absence of anti-CD2 in the panel (Table 1 ). An association between CD2 expression in the blast population of AML and inv(16) was documented in a prior study. 5 However, that 2-color flow cytometry study used gating techniques based purely on light scatter properties and probably could not distinguish a pure population of blasts versus some contaminating monocytes and lymphocytes. In the present study, CD2 was also detected on the blast population (as distinguished from the monocyte population) in four of six AMMLs with inv(16)/t(16;16). The blasts of NM-AML, in particular microgranular APL may also express CD2, 6 thus, this finding alone lacks specificity.
We found that all 11 cases of AMLs with 11q23 rearrangements in this series fell into the FAB M4 or M5 categories: nine AMoLs (eight monoblastic and 1 monocytic) and two AMMLs. Blasts in 10 of the 11 cases coexpressed CD36 and CD64; the remaining one was a group 2 AMML with 25% aberrant monocytes. In agreement with previous studies, no immunophenotypic features (other than monocytic differentiation) predicted the presence of an 11q23 rearrangement. 7 In summary, blasts of AMoL can be identified by coexpression of CD36 and CD64 with 96% sensitivity. Blasts of also AMML group 1 are CD36/CD64 positive. Therefore, it should be searched for more differentiated cells in order to separate AMML from AMoL when making the diagnosis upon immunological results. The coexpression pattern is seen in a small proportion of non-monocytic AMLs, including microgranular APL. This could be a potential diagnostic pitfall and requires correlation with other immunophenotypic features, cytomorphology, and cytogenetics. Furthermore, a well-defined population of monocytes (distinct from blasts) showing two or more aberrancies and CD2 expression was seen in all cases of AML with inv(16)(p13q22) and was 91% specific for this cytogenetic subgroup. Thus, in the context of AML, the presence of a distinct monocytic population with this unique immunophenotype should prompt evaluation for CBFb rearrangement.
Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia Chronic neutrophilic leukaemia (CNL) is a rare haematological disease of uncertain pathological aetiology. It has been recently defined as a chronic myeloproliferative disorder (CMPD) under the World Health Organization (WHO) classification, and is characterized by a persistent neutrophilia, splenomegaly and bone marrow (BM) hyperplasia. 1 Chronic neutrophilic leukaemia is of essence a diagnosis of exclusion, and affected patients have to be distinguished from other CMPD, such as chronic myelogenous leukaemia (CML), chronic myelomonocytic leukaemia and atypical CML. Causes of reactive neutrophilia need to be ruled out, and there should be no cytogenetic or molecular presence of the Philadelphia chromosome.
In the absence of a defining biological or molecular characteristic, the diagnosis of CNL is often challenging, and there have been approximately 150 reported cases in the literature. The overall outcome of these patients is poor, with the main causes of death owing to intracerebral haemorrhage, progressive neutrophilia or blast transformation. In a recent review of 40 cases, Elliot et al. 2 reported a median survival of 23.5 months (range: 1-106 months). At present, there is no consensus strategy on the treatment of these patients.
Several groups have recently independently identified a single somatic mutation on the JAK2 gene in patients with myeloproliferative disorders (MPDs). [3] [4] [5] [6] A guanine-to-thymine mutation encoding a valine-to-phenylalanine substitution at position 617 (V617F) in the JH2 domain of JAK2 disrupts the autoinhibitory function of JH2 and leads to constitutive JH1 tyrosine kinase activity and confers a growth factor-independent proliferative advantage on affected progenitor cells. 4, 5 This mutation is present in the majority of patients with polycythemia vera, and a large proportion of patients with either essential thrombocythaemia or idiopathic myelofibrosis. In contrast, this mutation is relatively uncommon in the other bcr/abl-negative MPDs, and is a rare event in patients with myelodysplastic syndromes. 7 Herein, we report the case of a 56-year-old woman diagnosed with CNL with the presence of the V617F JAK2 mutation. The patient presented with a 3-month history of lethargy and was discovered to have an elevated neutrophil count on a routine blood test. Her full blood count at diagnosis revealed a haemoglobin of 14.5 g/dl with an absolute white cell count of 39.1 Â 10 9 /l (neutrophil count of 33.3 Â 10 9 /l) and platelet count of 259 Â 10 9 /l. The presence of splenomegaly was confirmed by an abdominal ultrasound scan. Examination of a blood film revealed a mature neutrophilia with no increase in immature granulocytes or myeloblasts. The BM aspirate and trephine showed a hypercellular neutrophil granulocytosis with no evident dysplasia or increase in myeloblasts. Cytogenetic analysis confirmed a normal female 46 XX karyotype, and there was no detectable bcr/abl transcript on molecular analysis. Her past medical history included discoid eczema and gout (both of which were quiescent) and she was on allopurinol. There was no rise in her autoantibody titres, and inflammatory markers (C-reactive protein and erythrocyte sedimentation rate) were within normal limits. In accordance with the WHO classification, and in the absence of any other identifiable cause of her neutrophilia, she was thus diagnosed with CNL. She was initially commenced on hydroxyurea 500 mg once daily. Despite increasing her hydroxyurea dose to 1 g daily, her neutrophil count continued to rise. She is currently on a dose of busulphan 2 gm daily, which has controlled her symptoms. At present, she remains clinically stable 2.5 years from diagnosis.
DNA was either extracted from whole unfractionated peripheral blood or BM CD3, CD14, CD15, CD19, CD34, CD61 and glycophorin A-positive cells. Cells were isolated Pyrosequencing data from different cell lineages purified from bone marrow. The sequences shown are read from the reverse sequencing primer, which binds adjacent to the JAK2 mutated base (1849). Double height peaks indicate two consecutive bases of that type.
Letters to the Editor using antigen-specific, antibody-bound microbeads (Mittenyi Biotech, Survey, UK) on an AutoMacs cell separator (Mittenyi Biotech). In addition, haematopoietic progenitor cell-derived colonies were generated from BM aspirate low-density cells. Cultures were supplemented with granulocyte-macrophage colony-stimulating factor (GM-CSF) alone, GM-CSF with Epo and GM-CSF, Epo IL-3 and stem cell factor. Individual colonyforming units granulocyte/macrophage (CFU-GM)-derived colonies from GM-CSF-supplemented and fully supplemented cultures were harvested for JAK2 analysis by polymerase chain reaction (PCR). For PCR performed on haematopoietic colonies, colonies were placed directly into the PCR reaction without prior DNA extraction. Cell separation kits were used according to the manufacturer's instructions. The presence of the mutant JAK2 allele was detected using an allele-specific PCR (AS-PCR). 4 The presence of the mutation and the ratio of mutant to wildtype JAK2 allele were confirmed by pyrosequencing. Polymerase chain reaction products were generated using the AS-PCR primer sequences. Sequences were read from a reverse sequencing primer 5 0 -TCTCGTCTCCACAGA-3 0 . Pyrosequencing reactions were run on a Biotage PSQ HS 96 pyrosequencer.
Allele-specific polymerase chain reaction was used to detect the JAK2 V617F mutation in whole-blood, sub-fractionated BM and CFU-GM-derived haematopoietic colonies. The presence of the JAK2 V617F mutation was detected in whole peripheral blood and BM and was also found in all BM cell lineages with the exception of the lymphoid compartment (CD3-and CD19-positive cells). Day 14 cultures contained only CFU-GM-derived colonies. BFU-E-derived and mixed lineage colonies were not detected. All colonies picked and amplified by AS-PCR were positive for the V617F mutation (data not shown). Pyrosequencing of subfractionated BM cells confirms the presence of the JAK2 mutation in CD14-, CD15-, CD34-, CD61-and GPApositive cells and its absence in CD3-and CD19-positive cells (Figure 1 ). In addition, homo/heterozygosity calling by the Biotage software indicates that the mutation is homozygous and that the BM subcellular fractions are almost 100% clonal with respect to the JAK2 mutant allele.
Two other cases have recently described the concurrent presence of the JAK2 V17F mutation in the context of CNL with one case diagnosed with concurrent B-cell non-Hodgkin's lymphoma. 7, 8 Both case reports described the homozygous presence of the JAK2 mutation within granulocytes as observed in our case. In addition, we have also performed a lineagespecific analysis and our data demonstrate that the mutation is present in all myeloid and erythroid cells tested, but is absent from the lymphoid compartment. We have also found homozygous-mutated JAK2 present in 100% of CFU-GM-derived haematopoietic colonies. These observations concur with separate studies on patients with MPDs, which have shown that the JAK2 mutation is likely to occur as a myeloid lineage-specific mutation.
It remains unclear as to how a single somatic mutation can give rise to such a heterogeneous clinical presentation, and it seems likely that additional changes in either the signalling cascade or other genetic alterations may contribute to the disease phenotype. Our report adds to the observation that JAK2 mutation is not an infrequent event in CNL. All patients with newly diagnosed CNL should be screened to determine the true incidence of the mutation. Given the poor outcome of this disease, patients with CNL and JAK2 mutation should be considered as potential candidates for molecular-targeted therapy. 
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